Celsius Therapeutics, which has launched with series A capital, has become the latest Third Rock-launched company to be backed by GV.

Imprimis spun out Surface in 2017 to develop ocular surface treatments but its stake will be cut to 30% following Flying L Partners' investment.

The online video collaboration platform has closed its series A round at $13.9m after securing new funds from investors including You & Mr Jones.

Celsius Therapeutics, which has launched with series A capital, has become the latest Third Rock-launched company to be backed by GV.

Hearst Financial Venture Fund helped TruValue Labs, the developer of an AI-equipped data platform for investors, close the round at $13.6m.

The Cambridge spinout has raised $15m in series A funding from investors including Cambridge Enterprise and Parkwalk Advisors.

Lilly Asia Ventures and Sinopharm Healthcare Fund co-led the round that will fund a phase 3 trial for Ansun Biopharma's parainfluenza treatment.

Beam, a genetic medicine developer in which Editas Medicine is a shareholder, has emerged from stealth with an $87m series A round.

NUS spinout MediSix has obtained $20m from investors including Osage University Partners to commercialise research into leukaemia and lymphoma treatments.